Expert Insights
Hitting Diabetes Head-On: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists
Release Date: October 29, 2021
Expiration Date: October 28, 2022
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
Program Overview
Program Description
Type 2 diabetes (T2D) is a complex chronic disease that usually requires treatment intensification over time. Glucose-lowering agents with complementary mechanisms of action are recommended to better address the underlying pathophysiology. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an established pharmacologic option for T2D, targeting multiple metabolic derangements, and can be used at any stage of disease. In addition to robust glucose-lowering efficacy without increasing the risk for hypoglycemia, these agents have important pleiotropic effects on cardiovascular and renal risks, as well as body weight reduction. Leading guidelines have been updated to prioritize their use in people who would benefit most from these outcomes. This activity reviews the mechanism of action of GLP-1 RAs and provides practical advice for clinical implementation.
Format
eNewsletter with interactive benchmarking and video commentary
Learning Objectives
After completing this activity, participants should be better able to:
- Implement T2D guidelines in the selection of individualized treatment approaches
- Discuss the pathophysiology of T2D and the role of different classes of glucose-lowering agents in addressing the various aspects of T2D pathophysiology
- Describe similarities and differences between GLP-1 RAs in terms of glycemic management, weight effects, side effects, and cardiovascular/renal benefits
- Apply current evidence in the individualized selection of GLP-1 RAs to those with T2D
Target Audience
NPs and PAs
Faculty
Lucia M. Novak, MSN, ANP-BC, BC-ADM
- Nurse Practitioner
- Board Certified Adult Health and Advanced Diabetes Management
- President and Owner
- Diabetes Consulting Services
- North Bethesda, Maryland
- Co-Executive Director
- Capital Health & Metabolic Center
- Capital Diabetes & Endocrine Associates
- Camp Springs and Silver Spring, Maryland
Details
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until October 28, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Jennifer Wohl, DHSc, PA-C, Eastern Virginia Medica School, Norfolk, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from AbbVie Inc.; Astellas; Genentech, a member of the Roche Group; Novo Nordisk; Regeneron; and Urovant Sciences, Inc.
This activity is supported by an educational grant from Novo Nordisk.
Practicing Clinicians Exchange gratefully acknowledges the Institute for Medical and Nursing Education, Inc. (IMNE) for their contributions as an educational partner for this program.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Novak: consulting fees: Provention Bio, Sanofi; consulting fees/fees for non-CME/CE services: Abbott Diabetes Care, Janssen, Novo Nordisk, Xeris; fees for non-CME/CE services: AstraZeneca
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Review the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: October 29, 2021
Expiration date: October 28, 2022
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 102221C-7E